Atossa Genetics (ATOS) Reports Q3 Loss of $0.15/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BE
8. FIX
9. PNFP
10. NDAQ

Go back to Atossa Genetics (ATOS) Reports Q3 Loss of $0.15/Share

Atossa Genetics Announces Third Quarter 2015 Financial Results and Provides Company Update

November 12, 2015 4:01 PM EST

SEATTLE, WA -- (Marketwired) -- 11/12/15 -- Atossa Genetics, Inc. (NASDAQ: ATOS) today announced third quarter 2015 financial results and provided an update on recent company developments.

Dr. Steven C. Quay, Chairman, CEO & President, commented, "We are very pleased with our ongoing progress in establishing our two Phase II pharmaceutical clinical programs, topical Afimoxifene Gel and intraductal Fulvestrant, both of which have extensive patent portfolios. Today we are announcing that the National Cancer Institute has approved protocol development for a study to be funded by them using Afimoxifene Gel in their Cancer Prevention Clinical Trials... More